{
    "@context": {
        "schema": "https://schema.org/",
        "dct": "http://purl.org/dc/terms/",
        "hg": "https://hormuz.group/data/ns#"
    },
    "id": "hg:company:zist-darou-danesh-company",
    "identifier": "hg:company:zist-darou-danesh-company",
    "dataset_type": "entity_dataset",
    "entity_type": "company",
    "data_version": "2.0",
    "generated_by": "Hormuz Data Layer 0.2.1",
    "generated_at": "2026-07-04T02:51:17+00:00",
    "name": "Zist Darou Danesh Company",
    "slug": "zist-darou-danesh-company",
    "status": "publish",
    "url": "https://hormuz.group/companies/zist-darou-danesh-company/",
    "json_url": "https://hormuz.group/wp-content/uploads/hormuz-data/cpt/company/zist-darou-danesh-company.json",
    "rest_url": "https://hormuz.group/wp-json/hormuz-data/v1/cpt/company/zist-darou-danesh-company",
    "summary": "",
    "machine_summary": "Zist Darou Danesh Company Zist Darou Danesh Company is a private specialty pharmaceutical and biopharmaceutical company with a Tehran head office and manufacturing links to Alborz Province. In the Hormuz Group company graph, it matters because it connects recombinant medicines, specialty oncology and neurology products, orphan-drug access, advanced formulation capability, export certification, and Iran's movement toward higher-value pharmaceutical technology. Its profile is central to mapping Iran's domestic substitutes for expensive imported specialty drugs. Zist Darou Danesh is relevant for investors assessing Iran's specialty-drug market, biologics and recombinant medicine capability, oncology and neurology demand, orphan-drug access, export potential, and high-value pharmaceutical localization. It can support analysis of how domestic companies move into advanced therapies under sanctions, pricing regulation, and technology constraints. Due diligence should verify ownership, relationship with PMA or related holdings, GMP and EAEU GMP certification status, product registrations, export destinations, clinical evidence, pharmacovigilance systems, API and biologic input sourcing, manufacturing site status, and exposure to intellectual-property or regulatory risk. Zist Darou Danesh Company researches, develops, manufactures, and markets specialty medicines for complex diseases, including recombinant and chemical pharmaceutical products in oncology, neurology, orphan diseases, dermatology-rheumatology, iron deficiency, endocrinology, diabetes, MS, ALS, cancer, aesthetic drugs, and other specialized therapeutic areas. Its activity includes pharmaceutical R&D, patient support, clinical education, export registration, and GMP-based specialty-drug production. province: Tehran industry: Healthcare & Pharma, Pharmaceuticals market: Consumer Demand, Healthcare, Materials, Supply Chains challenges: Compliance, Data Gaps, Import Dependence, Technology Gap company_type: Manufacturer, Private Company city: Tehran",
    "published_at": "2026-06-28T20:29:05+00:00",
    "modified_at": "2026-06-28T20:29:05+00:00",
    "taxonomies": {
        "province": [
            {
                "id": 3,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/provinces/tehran/"
            }
        ],
        "industry": [
            {
                "id": 21,
                "name": "Healthcare & Pharma",
                "slug": "healthcare-pharma",
                "url": "https://hormuz.group/industry/healthcare-pharma/"
            },
            {
                "id": 121,
                "name": "Pharmaceuticals",
                "slug": "pharmaceuticals",
                "url": "https://hormuz.group/industry/healthcare-pharma/pharmaceuticals/"
            }
        ],
        "market": [
            {
                "id": 34,
                "name": "Consumer Demand",
                "slug": "consumer-demand",
                "url": "https://hormuz.group/market/consumer-demand/"
            },
            {
                "id": 69,
                "name": "Healthcare",
                "slug": "healthcare",
                "url": "https://hormuz.group/market/consumer-demand/healthcare/"
            },
            {
                "id": 73,
                "name": "Materials",
                "slug": "materials",
                "url": "https://hormuz.group/market/enterprise-demand/materials/"
            },
            {
                "id": 76,
                "name": "Supply Chains",
                "slug": "supply-chains",
                "url": "https://hormuz.group/market/enterprise-demand/supply-chains/"
            }
        ],
        "challenges": [
            {
                "id": 164,
                "name": "Compliance",
                "slug": "compliance",
                "url": "https://hormuz.group/challenges/regulatory-barriers/compliance/"
            },
            {
                "id": 187,
                "name": "Data Gaps",
                "slug": "data-gaps",
                "url": "https://hormuz.group/challenges/operational-risks/data-gaps/"
            },
            {
                "id": 176,
                "name": "Import Dependence",
                "slug": "import-dependence",
                "url": "https://hormuz.group/challenges/market-gaps/import-dependence/"
            },
            {
                "id": 179,
                "name": "Technology Gap",
                "slug": "technology-gap",
                "url": "https://hormuz.group/challenges/market-gaps/technology-gap/"
            }
        ],
        "company_type": [
            {
                "id": 299,
                "name": "Manufacturer",
                "slug": "manufacturer",
                "url": "https://hormuz.group/company-type/manufacturer/"
            },
            {
                "id": 307,
                "name": "Private Company",
                "slug": "private-company",
                "url": "https://hormuz.group/company-type/private-company/"
            }
        ],
        "city": [
            {
                "id": 384,
                "name": "Tehran",
                "slug": "tehran",
                "url": "https://hormuz.group/cities/tehran/"
            }
        ]
    },
    "taxonomy_labels": {
        "province": "Tehran",
        "industry": "Healthcare & Pharma, Pharmaceuticals",
        "market": "Consumer Demand, Healthcare, Materials, Supply Chains",
        "challenges": "Compliance, Data Gaps, Import Dependence, Technology Gap",
        "company_type": "Manufacturer, Private Company",
        "city": "Tehran"
    },
    "fields_summary": {
        "legal_name": "Zist Darou Danesh Company",
        "website": "https://zistdaru.com",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "",
        "listing_status": "private",
        "products_services": "Zist Darou Danesh Company researches, develops, manufactures, and markets specialty medicines for complex diseases, including recombinant and chemical pharmaceutical products in oncology, neurology, orphan diseases, dermatology-rheumatology, iron deficiency, endocrinology, diabetes, MS, ALS, cancer, aesthetic drugs, and other specialized therapeutic areas. Its activity includes pharmaceutical R&D, patient support, clinical education, export registration, and GMP-based specialty-drug production.",
        "export_relevance": "high",
        "short_profile": "Zist Darou Danesh Company is a private specialty pharmaceutical and biopharmaceutical company with a Tehran head office and manufacturing links to Alborz Province. In the Hormuz Group company graph, it matters because it connects recombinant medicines, specialty oncology and neurology products, orphan-drug access, advanced formulation capability, export certification, and Iran's movement toward higher-value pharmaceutical technology. Its profile is central to mapping Iran's domestic substitutes for expensive imported specialty drugs.",
        "investment_relevance": "Zist Darou Danesh is relevant for investors assessing Iran's specialty-drug market, biologics and recombinant medicine capability, oncology and neurology demand, orphan-drug access, export potential, and high-value pharmaceutical localization. It can support analysis of how domestic companies move into advanced therapies under sanctions, pricing regulation, and technology constraints. Due diligence should verify ownership, relationship with PMA or related holdings, GMP and EAEU GMP certification status, product registrations, export destinations, clinical evidence, pharmacovigilance systems, API and biologic input sourcing, manufacturing site status, and exposure to intellectual-property or regulatory risk."
    },
    "fields": {
        "rank_math_internal_links_processed": "1",
        "wp_statistics_words_count": "0",
        "legal_name": "Zist Darou Danesh Company",
        "city": "Tehran, Tehran Province, Iran",
        "ticker_symbol": "",
        "export_relevance": "high",
        "verification_status": "basic",
        "data_confidence": "high",
        "listing_status": "private",
        "last_updated": "29/06/2026",
        "website": "https://zistdaru.com",
        "products_services": "Zist Darou Danesh Company researches, develops, manufactures, and markets specialty medicines for complex diseases, including recombinant and chemical pharmaceutical products in oncology, neurology, orphan diseases, dermatology-rheumatology, iron deficiency, endocrinology, diabetes, MS, ALS, cancer, aesthetic drugs, and other specialized therapeutic areas. Its activity includes pharmaceutical R&D, patient support, clinical education, export registration, and GMP-based specialty-drug production.",
        "short_profile": "Zist Darou Danesh Company is a private specialty pharmaceutical and biopharmaceutical company with a Tehran head office and manufacturing links to Alborz Province. In the Hormuz Group company graph, it matters because it connects recombinant medicines, specialty oncology and neurology products, orphan-drug access, advanced formulation capability, export certification, and Iran's movement toward higher-value pharmaceutical technology. Its profile is central to mapping Iran's domestic substitutes for expensive imported specialty drugs.",
        "investment_relevance": "Zist Darou Danesh is relevant for investors assessing Iran's specialty-drug market, biologics and recombinant medicine capability, oncology and neurology demand, orphan-drug access, export potential, and high-value pharmaceutical localization. It can support analysis of how domestic companies move into advanced therapies under sanctions, pricing regulation, and technology constraints. Due diligence should verify ownership, relationship with PMA or related holdings, GMP and EAEU GMP certification status, product registrations, export destinations, clinical evidence, pharmacovigilance systems, API and biologic input sourcing, manufacturing site status, and exposure to intellectual-property or regulatory risk.",
        "source_note": "Based on public company, official-company, specialty-pharmaceutical, biopharmaceutical, recombinant-drug, GMP, export, product, and market-related information. Further verification is required before treating this profile as verified investment intelligence."
    },
    "field_profile": {
        "rank_math_internal_links_processed": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "wp_statistics_words_count": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "legal_name": {
            "type": "string",
            "present": true,
            "length": 25
        },
        "city": {
            "type": "string",
            "present": true,
            "length": 29
        },
        "ticker_symbol": {
            "type": "string",
            "present": false,
            "length": 0
        },
        "export_relevance": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "verification_status": {
            "type": "string",
            "present": true,
            "length": 5
        },
        "data_confidence": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "listing_status": {
            "type": "string",
            "present": true,
            "length": 7
        },
        "last_updated": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "website": {
            "type": "string",
            "present": true,
            "length": 20
        },
        "products_services": {
            "type": "string",
            "present": true,
            "length": 503
        },
        "short_profile": {
            "type": "string",
            "present": true,
            "length": 539
        },
        "investment_relevance": {
            "type": "string",
            "present": true,
            "length": 716
        },
        "source_note": {
            "type": "string",
            "present": true,
            "length": 258
        }
    },
    "sources": [
        {
            "type": "note",
            "value": "Based on public company, official-company, specialty-pharmaceutical, biopharmaceutical, recombinant-drug, GMP, export, product, and market-related information. Further verification is required before treating this profile as verified investment intelligence."
        }
    ],
    "quality": {
        "required_fields": [
            "legal_name",
            "website",
            "city",
            "listing_status",
            "products_services",
            "export_relevance",
            "verification_status",
            "data_confidence",
            "short_profile",
            "investment_relevance",
            "source_note",
            "last_updated"
        ],
        "missing_required_fields": [],
        "missing_required_count": 0,
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026",
        "stale_over_180_days": false,
        "quality_score": 100
    },
    "verification": {
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026"
    }
}